Founded with a mission to revolutionize cancer diagnostics, Precipio aims to provide the most accurate and efficient diagnostic advice to enhance patient care. The company offers proprietary hematology diagnostic products, including Bloodhound™ and HemeScreen® molecular kits, which detect various mutations related to blood cancers like MPN, CLL, and AML. Precipio focuses on improving laboratory throughput and economics while ensuring superior diagnostic accuracy for patients and physicians.
Precipio has garnered attention for its innovative approach to cancer diagnostics, attracting notable investors and partnerships within the medical and biotech sectors. The company's achievements include the development of advanced diagnostic tools that significantly enhance the speed and accuracy of hematology testing. By prioritizing precision and efficiency, Precipio has made a substantial impact on the quality of cancer diagnostics, ultimately contributing to better patient outcomes.
